Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS).
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial
Annals of Oncology | | R. Liu, J. Zhao, R. Zhang, B. Liu, Y. Liu, S. Li, Y. Chen, H. Yang, Z. Liu, Z. Li, Y. Qin, M. Huang, Y. Ba, H. Zhang, Y. Qu, Y. Du, T. Deng, M. Yang, X. Hou, C. Liu, F. Ning, Y.P. Liu, X. Wu, Y. Xie, Y. An, K. Zou, L. She, J. Xu
Topics: breast-cancer, blood-cancer, stomach-cancer, clinical-trials